NCT05104788View on ClinicalTrials.gov

A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

March 1, 2024

Study Completion Date

December 1, 2026

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Icotinib

Oral

DRUG

Cisplatin

Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles.

DRUG

Carboplatin

Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 2 cycles

DRUG

Pemetrexed

Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 2 cycles

Trial Locations (1)

100176

RECRUITING

BeijingCancerH, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER